
Feature|Articles|October 9, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
The Future of Precision Medicine Depends on More Than Biology
Author(s)Ben Hargreaves
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of biological targets allowed developers to design molecules that acted more precisely, as the evolution of JAK inhibitors for autoimmune disease in particular has demonstrated.
Related to this article

Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement


